What is it and what does it include?
The pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR (Rosiglitazone (Extended Release)) as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials. The study enrolled 14 patients (seven of each APOE genotype) 50 years or older. Each patient received a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples were taken up to 36h.